Cowen & Co. Maintains a Buy Rating on Scholar Rock Holding (SRRK)

By Ryan Adsit

Cowen & Co. analyst Marc Frahm maintained a Buy rating on Scholar Rock Holding (SRRKResearch Report) today. The company’s shares closed last Monday at $8.07, close to its 52-week low of $6.95.

According to TipRanks.com, Frahm is a 1-star analyst with an average return of -1.1% and a 53.8% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Allogene Therapeutics, and Odonate Therapeutics.

Currently, the analyst consensus on Scholar Rock Holding is a Moderate Buy with an average price target of $23.00, a 216.4% upside from current levels. In a report issued on November 13, Wedbush also maintained a Buy rating on the stock with a $23.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $30.00 and a one-year low of $6.95. Currently, Scholar Rock Holding has an average volume of 71.66K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Scholar Rock Holding Corp. is a biopharmaceutical company, which engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling.